Abstract

Overactive mitochondrial fission was shown to promote cell transformation and tumor growth. It remains elusive how mitochondrial quality is regulated in such conditions. Here, we show that upregulation of mitochondrial fission protein, dynamin related protein-1 (Drp1), was accompanied with increased mitochondrial biogenesis markers (PGC1α, NRF1, and Tfam) in breast cancer cells. However, mitochondrial number was reduced, which was associated with lower mitochondrial oxidative capacity in breast cancer cells. This contrast might be owing to enhanced mitochondrial turnover through autophagy, because an increased population of autophagic vacuoles engulfing mitochondria was observed in the cancer cells. Consistently, BNIP3 (a mitochondrial autophagy marker) and autophagic flux were significantly upregulated, indicative of augmented mitochondrial autophagy (mitophagy). The upregulation of Drp1 and BNIP3 was also observed in vivo (human breast carcinomas). Importantly, inhibition of Drp1 significantly suppressed mitochondrial autophagy, metabolic reprogramming, and cancer cell viability. Together, this study reveals coordinated increase of mitochondrial biogenesis and mitophagy in which Drp1 plays a central role regulating breast cancer cell metabolism and survival. Given the emerging evidence of PGC1α contributing to tumor growth, it will be of critical importance to target both mitochondrial biogenesis and mitophagy for effective cancer therapeutics.

Highlights

  • Metabolic and nutrient homeostasis is critical for cellular function and human health

  • An important question to be addressed is how mitochondrial quality control is regulated by overactive mitochondrial division

  • We employed bioinformatics approach analyzing 529 human breast cancer entities from The Cancer Genome Atlas (TCGA) database, and the results were validated by experimental biology in human breast cancer tissues and cell cultures

Read more

Summary

Introduction

Metabolic and nutrient homeostasis is critical for cellular function and human health. Mitochondrial alterations have been implicated in a variety of human metabolic diseases including cancer [1,2,3]. As such, increasing efforts have been made to explore cancer therapeutics by targeting mitochondria and the metabolic switch [4, 5, 7, 8]. Dysregulation of the dynamic processes impairs mitochondrial function and has been reported in cancer, diabetes, and neurodegenerative diseases [9, 10, 13]. Mitochondrial fission is upregulated due to Drp activation or overexpression in different types of tumors or cancers [14,15,16,17,18].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call